Notably, following the initial launch of the GLP-1 RA liraglutide in Japan, cases of diabetic ketoacidosis (DKA) and mortality were reported in insulin-dependent individuals who discontinued insulin therapy upon switching to liraglutide [13, 14]. The gene discussed is INS; the disease is diabetic ketoacidosis.